A debilitating, chronic disorder mediated by the irreversible loss of hypocretin/orexin (ORX) neurons, narcolepsy type 1 (NT1) is often misdiagnosed or underdiagnosed. Moreover, while there are a number of available therapies for NT1, many are associated with adverse effects and are symptomatic. However, novel agents that target the pathophysiology of NT1 have demonstrated efficacy and safety profiles in recent studies.
Join our expert faculty for this virtual Care Team Forum℠ symposium, featuring a series of panel discussions on recognition, pathophysiology, and treatment of NT1. Each panel topic will be augmented by the perspectives of an experienced patient with NT1, who will share valuable teaching moments from their therapeutic journey.
Upon successful completion of this education activity, participants should be better able to:
Albert Einstein College of Medicine
Bronx, New York, United States
Professor, Neurology and Physiology
Sleep Unit, Gui de Chauliac Hospital
University of Montpellier
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston Children’s Hospital
Boston, Massachusetts, United States
Featured RMEI CE Activities